• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

ATL awaits FDA extension of breast PMA

Article

ATL chairman and CEO Dennis Fill this month said he expects theFood and Drug Administration to approve within the next severalweeks the use of the company's flagship HDI 3000 scanner for differentiatingmalignant from benign solid breast lesions. ATL, of

ATL chairman and CEO Dennis Fill this month said he expects the

Food and Drug Administration to approve within the next several

weeks the use of the company's flagship HDI 3000 scanner for differentiating

malignant from benign solid breast lesions. ATL, of Bothell, WA,

already has FDA approval to differentiate solid breast lesions

using its older Ultramark 9 HDI scanner, and filed a supplemental

premarket approval application with the agency to extend the technique

to HDI 3000 (SCAN 4/24/96). Fill made the comments during a presentation

at the Bear Stearns Health Care Conference in New York City.

Recent Videos
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.